CT orders are pretty common and the requests are usually granted.
I don’t read much into them, especially for biotech companies whose value is largely tied to their IP.
I certainly don’t see the CR as presaging some kind of deal with a third party. Any third party that would be interested in buying SGYP or partnering with SGYP would know what they need to know, CT or no CT.
If I could afford to buy all of them, I would not need to buy any of them and I sure wouldn't be spending time on the message boards!